BD Announces Inaugural Members of Scientific Advisory Board

News provided by

May 02, 2022, 06:50 ET

Share this article

Share this article

Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology

FRANKLIN LAKES, N.J., May 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the inaugural members of the BD Scientific Advisory Board (SAB), which is comprised of top external medical key opinion leaders, science and technology experts and experienced innovation leaders.

The SAB will advise BD on the company's technology capabilities, innovation pipeline, tuck-in M&A opportunities, early-stage investments and growth prioritization, along with emerging trends in health care, science and technology, and the potential implications for BD.

"Innovation is the driving force in our strategy to grow and deliver an even more significant impact toward improving outcomes for patients and providers," said Tom Polen, chairman, chief executive officer and president of BD. "Our vision is to actively lead in emerging science that will transform health care. The scientific advisory board brings leading experts to help pressure-test our portfolio and strategy, while also providing real-world practicality for future technologies."

Inaugural members of the SAB include:

"We're at an inflection point where advances in science, technologies like data science and artificial intelligence, and new care models are opening up unprecedented opportunities to improve and reshape what health care looks like," said Joseph (Joe) Smith, MD, PhD, chief scientific officer at BD and co-chair of the SAB. "The board will help us build on our momentum by advising on evolving care pathways and emerging technologies that can enhance or disrupt our near- and long-term innovation pipelines to ensure we're creating the best solutions for the billions of patients we serve."

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

SOURCE BD (Becton, Dickinson and Company)

Modal title